←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Peptide Drug Conjugate
Heinz-Herbert Fiebig
MD
🏢Oncotest (Charles River)🌐Germany
Founder and Chief Scientific Officer
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Heinz-Herbert Fiebig founded Oncotest and developed one of the largest patient-derived xenograft panels used for cancer drug screening including peptide drug conjugates. His work has enabled preclinical evaluation of conjugate therapies. He is a leading figure in translational preclinical oncology.
Share:
🧪Research Fields 研究领域
patient derived xenografts
cancer drug screening
peptide drug conjugate testing
preclinical oncology
tumor models
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Heinz-Herbert Fiebig 的研究动态
Follow Heinz-Herbert Fiebig's research updates
留下邮箱，当我们发布与 Heinz-Herbert Fiebig（Oncotest (Charles River)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment